PolarityTE Inc PTE

NAS: PTE | ISIN: US7310941080   17/08/2023
0,067 USD (0,00%)
(0,00%)   17/08/2023

27 december 2022 · PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company · Persbericht

10 november 2022 · PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update · Persbericht

9 november 2022 · PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company · Persbericht

13 september 2022 · PolarityTE to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022 · Persbericht

8 september 2022 · PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors · Persbericht

11 augustus 2022 · PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update · Persbericht

1 augustus 2022 · PolarityTE to Report Q2 2022 Financial Results on August 11, 2022 · Persbericht

6 juni 2022 · PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules · Persbericht

23 mei 2022 · PolarityTE to Attend H.C. Wainwright Global Investment Conference · Persbericht

16 mei 2022 · PolarityTE to Effectuate 1-for-25 Reverse Stock Split · Persbericht

16 mei 2022 · PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update · Persbericht

13 mei 2022 · PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE® · Persbericht

6 mei 2022 · PolarityTE to Report Q1 2021 Financial Results on May 16, 2022 · Persbericht

3 mei 2022 · PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers · Persbericht

30 maart 2022 · PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update · Persbericht

16 maart 2022 · PolarityTE Announces Closing of $5.0 Million Registered Direct Offering · Persbericht

16 maart 2022 · PolarityTE Announces $5.0 Million Registered Direct Offering · Persbericht

10 maart 2022 · PolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022 · Persbericht

17 februari 2022 · PolarityTE Announces Allowance of Fourth U.S. Patent · Persbericht

18 januari 2022 · PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication · Persbericht

Mijn selecties